Treatment of hepatitis C virus infection and associated glomerular disease
Hepatitis C virus infection is a systemic disorder and can have various extrahepatic manifestations like hepatitis virus C associated glomerulonephritis. KDIGO recommends that all patients with hepatitis C virus infection be tested at least annually for proteinuria, hematuria and eGFR in order to de...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Amaltea Medical Publishing House
2020-09-01
|
| Series: | Romanian Medical Journal |
| Subjects: | |
| Online Access: | https://rmj.com.ro/articles/2020.3/RMJ_2020_3_Art-01.pdf |
| Summary: | Hepatitis C virus infection is a systemic disorder and can have various extrahepatic manifestations like hepatitis virus C associated glomerulonephritis. KDIGO recommends that all patients with hepatitis C virus infection be tested at least annually for proteinuria, hematuria and eGFR in order to detect a possible HCV-associated kidney disease. Immunossupressive therapy must be initiated in patients who have severe complications due to hepatitis virus C infection, but the clinicians must consider two aspects: hepatotoxicity and viral reactivation due to immunosuppression. As for antivirals, DAAs are now first-line treatment for management of HCV infection, even in CKD patients with advanced renal disease. In this review, we aimed to take a look on possible therapies for HCV-induced glomerulonephritis, the interactions beteween them and the impact of different therapies on renal and hepatic diseases. |
|---|---|
| ISSN: | 1220-5478 2069-606X |